Skip to content

Comparing Effects of Various Combinations of 6 Hertz(Hz) rTMS & LFrTMS on Motor Recovery Due to Cerebrovascular Disease

Series Study About the rTMS Effects on the Recovery of Limb Motor Dysfunction Due to Cerebral Vascular Disease, Part 1: Comparing the Effects of Various Combinations Between 6 Hertz(Hz) rTMS & LFrTMS.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03012204
Enrollment
120
Registered
2017-01-06
Start date
2017-02-16
Completion date
2018-12-31
Last updated
2017-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovascular Disease

Keywords

Cerebrovascular Disease, Repetitive Transcranial Magnetic Stimulation

Brief summary

To compare the effects of various combinations between 6 hertz(Hz) rTMS & LFrTMS on the limb motor dysfunction due to cerebral vascular disease.

Detailed description

It is the basic principle for functional recovery after cerebrovascular disease to restore the original balance in reciprocal inhibition between affected hemisphere and unaffected hemisphere. repetitive transcranial magnetic stimulation (rTMS) is a noninvasive neuroplastic technique rebalancing interhemispheric competition after stroke. Low frequency rTMS (LFrTMS) on contralesional hemisphere or high frequency rTMS (HFrTMS) on lesional hemisphere might be the basic choice. 6 hertz(Hz) primed LFrTMS on lesional primary motor cortex has the stronger effect than LFrTMS alone does on one hand; the other newly-developed combination, i.e. HFrTMS on lesional primary motor cortex and LFrTMS on contralesional primary motor cortex might also be more effective than they do respectively on the other hand. The main aim of our research is to find out which combination is better by considering both safety and efficiency.

Interventions

DEVICEreal LFrTMS at unaffected M1

Compare the effect of LFrTMS at unaffected M1 to that of all sham stimulation on motor rehabilitation after cerebrovascular disease . rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1. The four groups are the combinations of real or sham ①/②/③.

DEVICEreal primed LFrTMS at unaffected M1

Compare the effect of primed LFrTMS at unaffected M1 to that of LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease . rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1. The four groups are the combinations of real or sham ①/②/③.

DEVICEcombined rTMS at both M1

Compare the effect of combined rTMS at both M1 to that of primed LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease . rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1. The four groups are the combinations of real or sham ①/②/③.

DEVICEall sham stimulation

used as controls to eliminate the placebo effect of all kinds of combinated rTMS

Sponsors

Beijing Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Aged from 30 to 90 years; * Newly onset cerebral infarction or brain hemorrhage confirmed by MRI or CT; * the disease duration is less than 20 weeks when recruited into the trial; * no existence of limb motor dysfunction before this onset, and new occurrence of unilateral limb motor dysfunction after this onset; * the physical and mental condition are good enough to cooperate with the assessment and treatment; * the NIHSS score: total 5-20,1a,1b,1c=0; * the subject or legal guardian sign the consent form.

Exclusion criteria

* during pregnancy; * with skull defect; * with metal implants, cardiac pacemaker, cochlear implantation; * epileptiform discharge in EEG.

Design outcomes

Primary

MeasureTime frameDescription
Fugl-Meyer assessment (FMA)1) Before treatment (Baseline); 2) Change from Baseline FMA at the 1st workday after the last treatment; 3) Change from Baseline FMA at the 28th natural day after the last treatmentScore of Fugl-Meyer assessment
Simple Test for Evaluating Hand Function (STEF)1) Before treatment (Baseline); 2) Change from Baseline STEF at the 1st workday after the last treatment; 3) Change from Baseline STEF at the 28th natural day after the last treatmentScore of Simple Test for Evaluating Hand Function

Secondary

MeasureTime frameDescription
National Institute of Health Stroke Scale (NIHSS)1) Before treatment (Baseline); 2) Change from Baseline NIHSS at the 1st workday after the last treatment; 3) Change from Baseline NIHSS at the 28th natural day after the last treatmentScore of National Institute of Health Stroke Scale

Countries

China

Contacts

Primary ContactJin Xing, M.D.
zhuanglixingjin@163.com+86-13521278542
Backup ContactXinxin Ma, M.D
zhuanglixingjin@163.com+86-15901043667

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026